首页> 美国卫生研究院文献>other >Patterns of statin non-prescription in patients with established coronary artery disease: A report from a contemporary multicenter Japanese PCI registry
【2h】

Patterns of statin non-prescription in patients with established coronary artery disease: A report from a contemporary multicenter Japanese PCI registry

机译:已确定的冠状动脉疾病患者中他汀类非处方药的模式:来自当代多中心日本PCI注册中心的报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Statin therapy is regarded as an effective medication to reduce cardiovascular events in patients at higher risk for future incidence of coronary artery disease. However, very few studies have been conducted to examine its implementation in non-Western real-world practice. In this study, we sought to describe statin prescription patterns in relation to patient characteristics in a Japanese multicenter percutaneous coronary intervention (PCI) registry as a foundation for quality improvement. We studied 15,024 patients that were prospectively enrolled in the Japan Cardiovascular Database-Keio interhospital Cardiovascular Study Registry from January 2009 to August 2014. The overall discharge statin non-prescription rate was 15.2%, without significant interhospital (MOR = 1.01) or annual differences (MOR = 1.13) observed. Hierarchical multivariable logistic regression analysis accounting for regional differences revealed that the presence of chronic kidney disease was associated with higher rates of statin non-prescription (OR 1.87, 95% confidence interval, 1.69–2.08, p value <0.001), and higher age (per 1-year increase) showed a trend for prescription of low-intensity statin (OR 1.00, 95% confidence interval, 1.00–1.01, p value = 0.045) within the subset of PCI patients (N = 4,853) enrolled after the year 2011. Our study indicates that patients with chronic kidney disease and elderlies may be the primary targets for maximizing the beneficial effect of statin therapy in post PCI patients.
机译:他汀类药物疗法被认为是减少冠心病未来发生率较高风险患者中心血管事件的有效药物。但是,很少进行研究以检验其在非西方现实世界实践中的执行情况。在这项研究中,我们试图在日本多中心经皮冠状动脉介入治疗(PCI)注册表中描述与患者特征相关的他汀类药物处方模式,以此作为提高质量的基础。我们研究了2009年1月至2014年8月在日本心血管数据库-庆应医院间心血管研究注册中心登记的15,024例患者。他汀类药物总体非处方率为15.2%,无明显院际间(MOR = 1.01)或年度差异(观察到MOR = 1.13)。分层的多变量logistic回归分析说明了地区差异,显示慢性肾脏病的存在与他汀类药物非处方率较高(OR 1.87,95%置信区间,1.69–2.08,p值<0.001)和年龄较大(每增加1年)在2011年之后入组的PCI患者(N = 4,853)中,出现低强度他汀类药物处方的趋势(OR 1.00,95%置信区间,1.00–1.01,p值= 0.045)我们的研究表明,慢性肾脏病和老年患者可能是使他汀类药物治疗对PCI后患者的有益效果最大化的主要目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号